We appreciate Daniele Giacobbe’s Correspondence regarding the importance of colistin minimum inhibitory concentrations.
A study showed that both gradient-based and semi-automated devices can overestimate susceptibility to colistin. [...]

Additional Metadata
Persistent URL dx.doi.org/10.1016/S1473-3099(18)30223-8, hdl.handle.net/1765/105899
Journal The Lancet Infectious Diseases
Citation
Paul, M, Carmeli, Y, Daikos, G.L, Durante-Mangoni, E, Theuretzbacher, U, Mouton, J.W, & Leibovici, L. (2018). Colistin versus colistin plus meropenem for severe infections: Authors' reply. The Lancet Infectious Diseases, 18(5), 495–496. doi:10.1016/S1473-3099(18)30223-8


See Also
article
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria
M. Paul (Mical), G.L. Daikos (George), E. Durante-Mangoni (Emanuele), Yahav, D. (Dafna), Y. Carmeli (Yehuda), Benattar, Y.D. (Yael Dishon), Skiada, A. (Anna), Andini, R. (Roberto), Eliakim-Raz, N. (Noa), Nutman, A. (Amir), et al. Zusman, O. (Oren), A. Antoniadou (A.), Pafundi, P.C. (Pia Clara), Adler, A. (Amos), Dickstein, Y. (Yaakov), Pavleas, I. (Ioannis), Zampino, R. (Rosa), Daitch, V. (Vered), Bitterman, R. (Roni), Zayyad, H. (Hiba), Koppel, F. (Fidi), Levi, I. (Inbar), Babich, T. (Tanya), L.E. Friberg (Lena), J.W. Mouton (Johan), U. Theuretzbacher (Ursula) and L. Leibovici (Leonard)